NCT03603106View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

November 25, 2013

Primary Completion Date

April 17, 2015

Study Completion Date

April 17, 2015

Conditions
Healthy VolunteersBrain Lesion
Interventions
DRUG

P03277

"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."

DRUG

Placebo

"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."

Trial Locations (1)

2060

Clinical Pharmacology unit, SGS Life Science Services, Antwerp

Sponsors

Lead Sponsor

Guerbet
All Listed Sponsors
lead

Guerbet

INDUSTRY

NCT03603106 - Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions | Biotech Hunter | Biotech Hunter